- Home
- LSEA vs ETON Comparison
LSEA vs ETON Comparison
Compare LSEA & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSEA
- ETON
- Stock Information
- Founded
- LSEA 2013
- ETON 2017
- Country
- LSEA United States
- ETON United States
- Employees
- LSEA N/A
- ETON N/A
- Industry
- LSEA Homebuilding
- ETON Biotechnology: Pharmaceutical Preparations
- Sector
- LSEA Consumer Discretionary
- ETON Health Care
- Exchange
- LSEA Nasdaq
- ETON Nasdaq
- Market Cap
- LSEA 300.4M
- ETON 329.8M
- IPO Year
- LSEA N/A
- ETON 2018
- Fundamental
- Price
- LSEA $6.96
- ETON $14.22
- Analyst Decision
- LSEA Buy
- ETON Strong Buy
- Analyst Count
- LSEA 4
- ETON 3
- Target Price
- LSEA $13.75
- ETON $27.67
- AVG Volume (30 Days)
- LSEA 340.2K
- ETON 248.9K
- Earning Date
- LSEA 04-30-2025
- ETON 03-18-2025
- Dividend Yield
- LSEA N/A
- ETON N/A
- EPS Growth
- LSEA N/A
- ETON N/A
- EPS
- LSEA 0.47
- ETON N/A
- Revenue
- LSEA $1,550,337,000.00
- ETON $39,011,000.00
- Revenue This Year
- LSEA $4.04
- ETON $107.69
- Revenue Next Year
- LSEA $5.27
- ETON $65.50
- P/E Ratio
- LSEA $15.86
- ETON N/A
- Revenue Growth
- LSEA 28.13
- ETON 23.29
- 52 Week Low
- LSEA $6.54
- ETON $3.03
- 52 Week High
- LSEA $14.91
- ETON $18.41
- Technical
- Relative Strength Index (RSI)
- LSEA 42.32
- ETON 43.84
- Support Level
- LSEA $7.13
- ETON $12.73
- Resistance Level
- LSEA $7.79
- ETON $15.73
- Average True Range (ATR)
- LSEA 0.36
- ETON 0.93
- MACD
- LSEA 0.04
- ETON -0.01
- Stochastic Oscillator
- LSEA 30.99
- ETON 49.67
About LSEA Landsea Homes Corporation
Landsea Homes Corp is a homebuilding company. It designs and builds homes and sustainable master-planned communities in some of the nation's desirable markets. The company's segments include Arizona, California, Florida, Metro New York, and Texas. It derives a majority of revenue from home sales in Florida.
About ETON Eton Pharmaceuticals Inc.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.